z-logo
open-access-imgOpen Access
Heterogeneity of Cloned Cell Lines Established from a Transplantable Rat Malignant Fibrous Histiocytoma
Author(s) -
Yamate Jyoji,
Tajima Masanori,
Togo Masaharu,
Shibuya Kazumoto,
Ihara Miheko,
Kudow Satoru
Publication year - 1991
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1991.tb01846.x
Subject(s) - histogenesis , histiocyte , cytoplasm , biology , pathology , mesenchymal stem cell , organelle , cell , microbiology and biotechnology , immunology , immunohistochemistry , medicine , genetics
Four cloned cell lines, MT‐7, MT‐8, MT‐9 and MX‐10, were established from a transplantable malignant fibrous histiocytoma (MFH) of F344 rats to investigate the histogenesis of the tumor. Cells of MT‐7, MT‐9 and MT‐10 had fine structures characteristic of histiocytes, such as numerous cell processes, many lysosomes and well‐developed cytoplasmic organelles. They stained positively for histiocytic lysosomal and antigenic markers. In addition, MT‐9 cells contained microfllaments and well‐developed RER in their cytoplasm, suggesting that they may be facultative fibroblasts. MT‐8 cells stained weakly for histiocytic markers and had scant cytoplasmic organelles. They were identified as undifferentiated mesenchymal cells. The tumors induced in syngeneic rats by inoculating MT‐7 or MT‐10 consisted of a mixture of the pleomorphic, myxoid and storiform types of MFH, and those by MT‐9 were of the storiform type. Cells forming these tumors stained positively for histiocytic markers. Tumors induced by MT‐8 consisted of undifferentiated cells negative to these stainings. The histogenesis of MFH is surmised to be related to various differentiation stages shifting from undifferentiated cells to histiocytic cells capable of acting as facultative fibroblasts.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here